USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
Sterling biomedical
Address:
2 DURHAM DR
Lynnfield, MA 01940-1238
Phone:
N/A
URL:
N/A
EIN:
262577114
DUNS:
15833702
Number of Employees:
2
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $334,593.00 2
SBIR Phase II $418,443.00 1

Award List:

SBIR Phase I:A Novel Antimicrobial Polymer for Medical Devices

Award Year / Program / Phase:
2010 / SBIR / Phase I
Award Amount:
$184,614.00
Agency:
NSF
Principal Investigator:
Abstract:
This Small Business Innovation Research Phase I project addresses the issue of costly and fatal infections associated with polymer-based, implantable medical devices. Device infections occur when bacteria adhere to the polymer surface, forming a biofilm that can be 100 to 1,000 times less… More

SBIR Phase I: Cost-Effective Anastomotic System Featuring Compliant Anastomoses

Award Year / Program / Phase:
2011 / SBIR / Phase I
Award Amount:
$149,979.00
Agency:
NSF
Principal Investigator:
Abstract:
This Small Business Innovation Research (SBIR) Phase I project aims to develop a mechanical system for facilitating vascular anastomoses (end-to-side, end-to-end) technology that allows for the rapid and reproducible production of a non-penetrating, compliant vascular reconstruction. This one-shot… More

SBIR Phase II: A Novel Antimicrobial Polymer for Medical Devices

Award Year / Program / Phase:
2011 / SBIR / Phase II
Award Amount:
$418,443.00
Agency:
NSF
Principal Investigator:
Abstract:
This Small Business Innovation Research (SBIR) Phase II project aims to develop an antimicrobial polymer technology with silver compounded into the catheter matrix, which allows for antimicrobial action expected to last several months. This cost-effective antimicrobial polymer technology prevents… More